TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24525635
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 to 60 mg/d) + Placebo
Study: 23298508
Drug: Serenoa repens
Normalized name: Serenoa Repens Fruit
DrugBank: Saw palmetto (DB14360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serenoa repens 320 mg every day for 24 months
Study: 23298508
Drug: Finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 1 mg every day for 24 months
Study: 19478343
Drug: Rhodiola rosea
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola rosea extract, 100 mg twice daily for 4 weeks
Study: 15904630
Drug: Omapatrilat 80
Normalized name: OMAPATRILAT
DrugBank: Omapatrilat (DB00886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omapatrilat 80 mg/day
Study: 12683707
Drug: Domiciliary pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domiciliary pulmonary rehabilitation program (walking, breathing exercises, postural drainage, controlled coughing, lifestyle changes) for 30 minutes twice daily for four weeks
Study: 7557824
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth (CBS) 240 mg bid for 4-8 weeks, followed by placebo maintenance treatment
Study: 7557824
Drug: Famotidine 40
Normalized name: famotidine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 40 mg nocte for 4-8 weeks, followed by 20 mg for 12 months after healing
Study: 16930802
Drug: L-Theanine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Theanine at the start of the experimental procedure
Study: 16930802
Drug: L-Theanine midway
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-Theanine midway through the experimental procedure
Study: 23229858
Drug: Cilobradine 0.25-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilobradine 0.25-5 mg doses
Study: 18763638
Drug: Grape procyanidins
Normalized name: procyanidin A2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grape procyanidins (GPC) 100 mg/day for 60 days
Study: 18763638
Drug: Starch capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starch capsule (control)
Study: 17182445
Drug: Cocaine pharmacotherapy
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine pharmacotherapy
Study: 27741192
Drug: Intra-fetal digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-fetal digoxin (1.0 mg)
Study: 27741192
Drug: Intra-amniotic digoxin
Normalized name: Digoxin
DrugBank: Digoxin (DB00390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intra-amniotic digoxin (1.0 mg)
Study: 16025963
Drug: Xinfang rhinitis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinfang rhinitis capsule (Control)
Study: 1987744
Drug: Multiagent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiagent chemotherapy regimen of CAP
Study: 6398833
Drug: Oxamniquine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxamniquine (15 mg/kg)
Study: 31752815
Drug: standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard group therapy
Study: 23317480
Drug: Elaborated VF
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Elaborated VF (VF plus cognitive preparation and cognitive review)
Study: 16187232
Drug: Immunotherapy (aPBSC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (aPBSC transplant with IL-2 incubation for 24 hours followed by parenteral IL-2 for 5 days, then 2 days of rest for 4 weeks)
Study: 8652333
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg on the evening before and 40 mg on the morning of surgery
Study: 8652333
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg on the evening before surgery and 2 h before anaesthesia
Study: 28982956
Drug: Topical medication
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medication without laser
Study: 18181978
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg daily for 42 days
Study: 12791570
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of the NMDA receptor antagonist memantine
Study: 6347380
Drug: Netilmicin, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Netilmicin, 2 mg/kg every eight hours for a minimum of 72 hours
Study: 6347380
Drug: Tobramycin, 1
Normalized name: Tobramycin, 10 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin, 1 mg/kg every eight hours for a minimum of 72 hours
Study: 22816213
Drug: L2-3 spinal
Normalized name: bovine spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L2-3 spinal anesthesia with 15 mg 0.5% isobaric bupivacaine
Study: 22816213
Drug: L3-4 spinal
Normalized name: bovine spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L3-4 spinal anesthesia with 15 mg 0.5% isobaric bupivacaine
Study: 12381637
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day amiloride (one month)
Study: 2180493
Drug: Chlorambucil (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorambucil (0.1 mg/kg/d)
Study: 25325454
Drug: 17β estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17β estradiol 0.5 mg/day
Study: 25325454
Drug: venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: venlafaxine XR 75 mg/day
Study: 21542914
Drug: Hip school
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip school + Manual therapy (group B) - 6 weeks, 5 sessions of hip school + manual therapy twice a week
Study: 7942533
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg aspirin
Study: 7942533
Drug: 162 mg
Normalized name: aspirin 162 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 162 mg aspirin
Study: 11475709
Drug: Philips/Jordan electric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Philips/Jordan electric toothbrush with CPS set at various levels (150-420 g)
Study: 2196627
Drug: Clomipramine (CMI)
DrugBank: Clomipramine (DB01242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomipramine (CMI) up to 300 mg daily for up to 10 weeks
Study: 28220020
Drug: CAP (1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP (1,000 mg/m2 orally twice daily, days 1-14)
Study: 12970273
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg, three times daily)
Study: 12970273
Drug: Dianette (ethinyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dianette (ethinyl estradiol, 35 micro g; cyproterone acetate, 2 mg)
Study: 8909666
Drug: H1 receptor
Normalized name: Histamine H1 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 receptor blocker (terfenadine 60 mg)
Study: 8909666
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor blocker (ranitidine 300 mg)
Study: 8909666
Drug: H1 and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: H1 and H2 receptor blockers (terfenadine 60 mg and ranitidine 300 mg)
Study: 6222473
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g mezlocillin given during induction of anesthesia
Study: 3990155
Drug: Phenobarbitone treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenobarbitone treatment
Study: 24405796
Drug: 1% lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% lidocaine intracervical injection
Study: 24405796
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of 2% lidocaine gel
Study: 22863639
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no cream or oil)
Study: 12881822
Drug: Transcutaneous electric
Normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcutaneous electric nerve stimulation (TENS) therapy
Study: 8692532
Drug: No G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No G-CSF (no cytopenia)
Study: 8692532
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no G-CSF despite insufficient leukocyte recovery)
Study: 1656181
Drug: rHu‐EPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHu‐EPO treatment (3 X 80 IE/kg/week for six months)
Study: 1656181
Drug: rHu‐EPO treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHu‐EPO treatment
Study: 7110806
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of fenoterol by nebulizer
Study: 7110806
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg of epinephrine followed by 0.75 mg of Sus-Phrine
Study: 26829066
Drug: Egg phospholipids
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Egg phospholipids preparation (45 ml, 15 ml 3 times per day)
Study: 18217220
Drug: Vocational rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vocational rehabilitation programs during inpatient treatment
Study: 22575569
Drug: Propofol (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (1.0 mg/kg IV initially, then adjusted based on response)
Study: 16156112
Drug: Fentanyl HCl
Normalized name: fentanyl HCl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl HCl PCTS 40 microg, 6, 18, 36 and 80 doses over 1, 3, 6 and 13.33 hours
Study: 11982795
Drug: Sodium thiopental
Normalized name: Thiopental Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium thiopental (5 mg/kg)
Study: 9516618
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel and concurrent radiation for 6 weeks with no adjuvant chemotherapy
Study: 9516618
Drug: Weekly paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Weekly paclitaxel and carboplatin with hyperfractionated radiation, followed by two cycles of adjuvant paclitaxel and carboplatin
Study: 9516618
Drug: Concurrent weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Concurrent weekly paclitaxel plus radiation
Study: 9516618
Drug: Paclitaxel, carboplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel, carboplatin, and radiation therapy
Study: 23024219
Drug: Low phosphate
Normalized name: Dianeal Low Calcium 1.5 Intraperitoneal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low phosphate plus phosphate binder (aluminum hydroxide, 500 mg thrice daily with meals)
Study: 19387475
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous ghrelin treatment
Study: 8607589
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg subcutaneously every 12 hours)
Study: 9308789
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg testosterone oenanthate (TE) weekly i.m. injections
Study: 7871362
Drug: Tactile sensibility
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactile sensibility of tooth 11 and its antagonists
Study: 29766842
Drug: Once-daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral antibiotic prophylaxis using either 50 mg of nitrofurantoin, 100 mg of trimethoprim, or 250 mg of cefalexin for 12 months
Study: 29766842
Drug: Once-daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily oral antibiotic prophylaxis
Study: 17075851
Drug: Risedronate (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (5 mg/day, 15 mg/day, 35 mg/week in Europe, 50 mg/week in North America)
Study: 10771879
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A (100,000 IU) with measles vaccine
Study: 10771879
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with measles vaccine
Study: 28669666
Drug: Nutriose®06 (resistant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutriose®06 (resistant dextrin) 10 g/d for 8 weeks
Study: 24965504
Drug: Dexpramipexole (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexpramipexole (75 mg and 150 mg single doses)
Study: 16175132
Drug: Pliva Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pliva Cyclosporine Soft Gelatin Capsules (USP Modified)
Study: 16175132
Drug: Neoral (cyclosporine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral (cyclosporine soft gelatin capsules, USP Modified)
Study: 12789824
Drug: Betaserc (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaserc (16 mg, 3 times daily before meal)
Study: 3829014
Drug: Primary chemotherapy
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary chemotherapy with doxorubicin and vincristine, surgery, or radiotherapy followed by additional chemotherapy with the same drug regimen
Study: 24726579
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication (olanzapine, perphenazine, quetiapine, risperidone, ziprasidone)
Study: 20634666
Drug: Full construct
Normalized name: Alstonia constricta bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full construct vaccine (recombinant fowlpox virus carrying genes for HIV Gag-Pol and IFN-gamma)
Study: 16164709
Drug: C. indicum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C. indicum extract-based cream (n = 125)
Study: 30008985
Drug: Levocetirizine 5
Normalized name: Levocetirizine 5mg Oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levocetirizine 5 mg/day
Study: 1531215
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy plus etanidazole (2 g/m2 i.v. 30 to 60 min before radiotherapy each Monday, Wednesday, and Friday to 34 g/m2 in 17 doses)
Study: 2939214
Drug: Ketanserin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (40 mg twice daily)
Study: 30321655
Drug: Once-daily GSP301
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily GSP301 (665 μg olopatadine and 50 μg mometasone)
Study: 30321655
Drug: Twice-daily GSP301
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily GSP301 (665 μg olopatadine and 25 μg mometasone)
Study: 14589256
Drug: Medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical care without physical therapy
Study: 12879543
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg/day
Study: 376131
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg 3 times daily) plus Medroxyprogesterone acetate (100 mg once daily)
Study: 376131
Drug: Tamoxifen (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (10 mg 3 times daily)
Study: 31679821
Drug: OM3-PL/FFA 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-PL/FFA 1 g/d
Study: 31679821
Drug: OM3-PL/FFA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM3-PL/FFA (all doses)
Study: 19232936
Drug: two mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: two mg of butorphanol in 10 mL of normal saline (Group 1)
Study: 15095233
Drug: Cetirizine, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine, 10 mg q.d. for 6 weeks
Study: 11546717
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg with fentanyl 0.02 mg
Study: 11546717
Drug: Intrathecal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal bupivacaine 15 mg and preservative-free morphine 200 microg without fentanyl (Control group)
Study: 1115014
Drug: 1.4 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 g/kg body weight protein intake
Study: 1115014
Drug: 2.8 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.8 g/kg body weight protein intake
Study: 1115014
Drug: 100 g
Normalized name: Berri-Freez 4.5 GM per 100 GM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 g of protein/day
Study: 31722153
Drug: Secondary surgical
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary surgical cytoreduction followed by platinum-based chemotherapy
Study: 18285619
Drug: Lisdexamfetamine in
Normalized name: Product containing lisdexamfetamine in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisdexamfetamine in solution
Study: 18285619
Drug: 70 mg
Normalized name: silybin 70 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg lisdexamfetamine capsule with high-fat meal
Study: 16540958
Drug: Propofol by
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol by continuous infusion
Study: 16540958
Drug: Lorazepam by
Normalized name: Lorazepam
DrugBank: Lorazepam (DB00186)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lorazepam by intermittent bolus administration
Study: 9175220
Drug: IABP treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IABP treatment for 2 hours prior to CPB
Study: 31221280
Drug: Low sodium
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sodium diet (LS: 3 g/day of dietary sodium chloride)
Study: 29343128
Drug: brexpiprazole 2-3
Normalized name: brexpiprazole 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 2-3 mg/day
Study: 29343128
Drug: quetiapine XR
Normalized name: quetiapine Extended Release Oral Tablet
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: quetiapine XR 150-300 mg/day
Study: 17686441
Drug: Erlotinib versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib versus chemotherapy
Study: 17686441
Drug: Erlotinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib monotherapy in recurrent disease
Study: 10484950
Drug: Melatonin 5.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 5.0 mg at bedtime
Study: 10484950
Drug: Melatonin 0.5
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.5 mg at bedtime
Study: 10484950
Drug: Melatonin 0.5
Normalized name: melatonin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin 0.5 mg taken on a shifting schedule
Study: 8733853
Drug: Topical flurbiprofen
Normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical flurbiprofen 0.03% solution applied every 15 minutes for 60 to 75 minutes before surgery
Study: 8733853
Drug: Topical indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical indomethacin 1% suspension applied every 15 minutes for 60 to 75 minutes before surgery
Study: 6753557
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg 3 times daily)
Study: 30995295
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with 2,850 kcal/kg and 16% CP
Study: 30995295
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with 2,950 kcal/kg and 16.5% CP
Study: 30995295
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with 3,050 kcal/kg and 17.0% CP
Study: 30995295
Drug: Dietary treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary treatment with 3,150 kcal/kg and 17.5% CP
Study: 12468909
Drug: Urokinase-heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urokinase-heparin (5000 IU)
Study: 25676588
Drug: Triptorelin (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin (120 μg/kg body weight)
Study: 22091799
Drug: Blue-light LED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue-light LED therapy
Study: 3300175
Drug: Conventional injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional injection treatment (CIT)
Study: 27139012
Drug: FE 999049
Normalized name: Fe
DrugBank: Ferric cation (DB13949)
Approvals — FDA: no, EMA: no, PMDA: no
Description: FE 999049 (225 IU subcutaneous dosing)
Study: 23930726
Drug: Zinc bis-glycinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc bis-glycinate 15 mg once a day for 3 months
Study: 9755737
Drug: Persistence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistence of subthreshold depressive symptoms 7 months after initiation of antidepressant therapy
Study: 1276696
Drug: Intra-amniotic prostaglandin
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-amniotic prostaglandin F2 alpha (25 mg repeated in six hours)
Study: 1276696
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (200 ml 20% NaCl)
Study: 31943257
Drug: APT-1011 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: APT-1011 (2 3-mg orally disintegrating tablets) under hs dosing
Study: 23336348
Drug: Recombinant tissue
Normalized name: Tissue plasminogen activator, recombinant
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recombinant tissue Plasminogen Activator (0.9 mg/kg, maximum dose 90 mg)
Study: 29440045
Drug: Acupuncture plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture plus rescue medication (RM)
Study: 29440045
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication (RM) alone
Study: 20117364
Drug: Clinically managed
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinically managed treatment
Study: 17622343
Drug: Agalsidase alfa
Normalized name: Agalsidase alfa
DrugBank: Agalsidase alfa (DB15874)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Agalsidase alfa (0.2 mg/kg biweekly)
Study: 17622343
Drug: Agalsidase beta
Normalized name: Agalsidase beta
DrugBank: Agalsidase beta (DB00103)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Agalsidase beta (0.2 mg/kg biweekly)